about
DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytesDendritic cells in islets of Langerhans constitutively present beta cell-derived peptides bound to their class II MHC moleculesThe central role of antigen presentation in islets of Langerhans in autoimmune diabetesZnT8-reactive T cells are weakly pathogenic in NOD mice but can participate in diabetes under inflammatory conditionsA minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes.The pancreas anatomy conditions the origin and properties of resident macrophages.Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells.Entry of diabetogenic T cells into islets induces changes that lead to amplification of the cellular response.Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouseRNA sensor-induced type I IFN prevents diabetes caused by a β cell-tropic virus in miceUnique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes.In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model.Beta cells transfer vesicles containing insulin to phagocytes for presentation to T cells.Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes.Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection.Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet functionPathogenic CD4⁺ T cells recognizing an unstable peptide of insulin are directly recruited into islets bypassing local lymph nodes.Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation.Antigen presentation events in autoimmune diabetes.Antibody Standardization to Benefit Biomedical ResearchHeavy/light chain assay for monitoring IgA multiple myeloma: digging out the IgA from the β regionIslet autoantibodies and type 1 diabetes: does the evidence support screening?Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk
P50
Q24644085-6C839F9F-C584-4005-9333-88EF11850FD8Q30481754-8A80E453-2FD8-48DC-B77A-AF4D6F9AEA6BQ33986306-537BC980-C2EF-4701-B966-CBED17F15F41Q34227916-0D4E34EA-D395-4F15-B51A-DF55D5906A14Q34452991-20705762-2571-4774-A573-562579040796Q34492976-502B6453-8D80-48E2-8131-68C1227BF7B0Q34504674-C2ADB57C-2489-44E9-A7C8-31C95F9E48E8Q34533933-F7C4559D-68F9-46D7-8D08-6F29A285D2F8Q34651934-976DC805-8481-494F-AC59-0A0104F94F03Q34755163-87B3FDFE-E3D8-4647-8BA9-AB61ACB8DDF3Q34831727-8CA04603-2E7D-4AAC-BC9A-486ECAF71497Q35569859-561858AE-7818-42FF-88A8-5F11B847DA07Q36155053-49C6036D-40B2-40FA-AA4D-B815654C1A30Q36228530-0CE32478-5F6D-461A-9486-1E7471A44B10Q36399581-92444421-3F3C-4562-851A-86220698B0A7Q37031073-2B54D128-F8D9-4FF3-BAE7-59A9B60DDEF7Q37246540-D982F8D4-B3AF-4328-A9FE-C791B08DAA44Q37581780-6907434A-BF58-4237-85D1-2E29EE8C7271Q37969489-5BACBD84-3E40-4215-988A-1FC27DD81C82Q85669935-DFF7AAA1-3B73-421C-9AB2-04C6919C5B4CQ86268137-B5646A55-A7C8-4866-8C4E-10DF3F777D79Q86993959-8BE60E45-0A4D-4CE5-B93C-568D5B1A7C81Q92110303-0BD3BA86-08B8-42FC-9922-F5EDEC3681DD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Boris Calderon
@ast
Boris Calderon
@en
Boris Calderon
@es
Boris Calderon
@nl
Boris Calderon
@sl
type
label
Boris Calderon
@ast
Boris Calderon
@en
Boris Calderon
@es
Boris Calderon
@nl
Boris Calderon
@sl
prefLabel
Boris Calderon
@ast
Boris Calderon
@en
Boris Calderon
@es
Boris Calderon
@nl
Boris Calderon
@sl
P106
P1153
23481457600
P21
P31
P496
0000-0003-1575-0739